Purpose Patients with lupus are chronically exposed to anti-inflammatory and immunosuppressive treatments that are associated with considerable morbidities. This study aimed to describe treatment ...

Description The presence of antinuclear antibody (ANA) is usually considered a hallmark of Systemic Lupus Erythematosus (SLE). However, a small group of SLE patients had the typical clinical ...

Background Discoid lupus erythematosus (DLE) is one of the LE-specific skin diseases on the scalp, and some cases induce scarring alopecia. In systemic LE (SLE), variable nail changes not specific to ...

Background Immunoglobulin gamma-3 subclass, also called the immunoglobulin gamma 3 chain C (IGHG3), normally comprises 5%–8% of all IgG in humans. The salivary IGHG3 was increased in Korean patients ...

Background Lupus nephritis (LN) is a common manifestation of systemic lupus erythematosus (SLE), with 10–30% progressing to end-stage renal disease (ESRD) and requiring dialysis. Kidney ...

Background We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices. Methods We employed urine ...

Background Often, patients present with clinical symptoms and immunologic abnormalities suggestive of systemic lupus erythematosus(SLE), while not meeting classification criteria yet. This is referred ...

Description Due to oral bleeding, a 34-year-old male patient was admitted to the hospital. Additionally, he developed hematochezia as a result of an anal fissure brought on by a hard stool. In the ...

Background Mutations, both activating and inactivating ones, continue to be identified in human diseases, including systemic lupus erythematosus (SLE). One emphasis is on mutations in transcription ...

Background Belimumab in conjunction with mycophenolate mofetil has been proven to be effective for treating systemic lupus erythematosus (SLE) in several randomized controlled trials. Usefulness of ...

Background Although the safety profile of COVID-19 vaccines was shown to be acceptable in the clinical trials, risk and benefit of the vaccines in patients with systemic lupus erythematosus (SLE) are ...

Background Despite the advances in the management of systemic lupus erythematosus (SLE), mortality rate among patients with SLE significantly remained higher compared to non-SLE over time. Serious ...